Brought to you by 
Vical gets global rights to Astellas' preclinical antifungal
20 Feb 2019
Executive Summary
Astellas Pharma Inc. licensed Vical Inc. exclusive worldwide rights to develop, commercialize, and manufacture its preclinical antifungal candidate ASP2397 for invasive Aspergillus infections.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vical gets global rights to Astellas' preclinical antifungal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice